LASN01
Thyroid Eye Disease (TED)
Key Facts
About Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotechnology company developing antibody therapies targeting the IL-11 pathway for fibrotic diseases. Its lead asset, LASN01, is an anti-IL-11 receptor antibody currently in Phase 1 trials for Thyroid Eye Disease (TED), with plans to advance to Phase 2. The company is well-capitalized following an oversubscribed $85 million Series B financing in December 2023, which will also fund IND-enabling studies for a second program, LASN500. Lassen's strategy is centered on creating best-in-class biotherapeutics for conditions with high unmet medical need.
View full company profileAbout Lassen Therapeutics
Lassen Therapeutics is a clinical-stage biotechnology company developing antibody therapies targeting the IL-11 pathway for fibrotic diseases. Its lead asset, LASN01, is an anti-IL-11 receptor antibody currently in Phase 1 trials for Thyroid Eye Disease (TED), with plans to advance to Phase 2. The company is well-capitalized following an oversubscribed $85 million Series B financing in December 2023, which will also fund IND-enabling studies for a second program, LASN500. Lassen's strategy is centered on creating best-in-class biotherapeutics for conditions with high unmet medical need.
View full company profileTherapeutic Areas
Other Thyroid Eye Disease (TED) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oral K9 | Inflammasome Therapeutics | Phase I |
| Batoclimab | Immunovant | Phase 3 |
| IMVT-1402 | Immunovant | Phase 2 |
| VRDN-001 | Viridian Therapeutics | Phase 3 |
| VRDN-003 | Viridian Therapeutics | Phase 1/2 |